<DOC>
	<DOC>NCT01082562</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability, serum concentrations and pharmacodynamic effects on serum low-density lipoprotein (LDL) cholesterol of single and multiple subcutaneous and intravenous doses of BMS-844421 in healthy subjects (SAD) and in subjects with elevated cholesterol (MAD).</brief_summary>
	<brief_title>Safety Study of BMS-844421 for Treatment of Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Healthy Subjects (SAD) Healthy Subjects (MAD) with untreated elevated cholesterol Body Mass Index (BMI) of 18 to 30 kg/mÂ² inclusive Women who are not of childbearing potential and men, ages 18 to 45 Any significant acute or chronic medical illness History of liver or renal disorders Prior use of any prescription or overthecounter lipid lowering drugs, within 8 weeks prior to study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>